Interestingly, an in vitro study has shown that programmable base editing of mutated pTERT blocked the binding of members of the ETS1 transcription factors to the TERT promoter, reduced TERT transcription and TERT protein expression, and induced senescence in glioma cell lines, suggesting that targeting pTERT mutations could be used as a therapeutic approach in cancer management (Li et al. 2020). Here, ETS1 is linked to central nervous system cancer.